MSTN and sarcopenia: Other myostatin inhibitors have been tested in patients with different muscle wasting conditions including sarcopenia, cachexia, and adult muscular dystrophies [28], but none have demonstrated the required efficacy in functional endpoints to allow regulatory approval.